HDL-C in Cardiac Syndrome X (HIRICS-X)

Bursa Yüksek İhtisas Education and Research Hospital

Status: Completed

Conditions: Microvascular Angina; Unstable Angina; Cardiovascular Diseases; Myocardial Ischaemia; Heart Diseases

Study type: Observational

Funder types: Other

Identifiers

NCT02095964

BYIEAH-281

Details and patient eligibility

About

High density lipoprotein cholesterol (HDL-C) is in the centrum of the process of reverse cholesterol transport from peripheral cells to the liver[10]. HDL-C promotes endothelial generation of nitric oxide (NO) and improves endothelial function and arterial vasoreactivity[11]. In several studies, lower HDL-C level was reported to be associated with increased coronary artery disease (CAD) risk[12-14]. HDL-C also has anti- inflammatory and anti-oxidant activities[15,16]. Concerning anti-inflammatory activity, HDL-C inhibits the activation of monocytes/macrophages and neutrophils[17,18] and inhibits the expression of endothelial adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) and E-selectin[15].

In this study we aimed to investigate the relation of HDL-C level with systemic inflammatory markers in patients with cardiac syndrome X (CSX).

Enrollment: 710 patients

Sex: All

Ages: 47 to 58 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Must be able to get exercise stress test
• Must be able to have coronary angiography
• Clinical diagnosis of typical anginaduring rest or effort
• Abnormal test result for exercise ECG or myocardial perfusion scintigraphy
• Must have of angiographically normal epicardial coronary arteries

Exclusion criteria

• Patients with valvular heart disease (mitral stenosis and moderate to severe mitral regurgitation
• Patients with moderate to severe aortic stenosis and regurgitation including mitral annular calcification)
• Patients with heart failure (left ventricular ejection fraction <50%)
• Patients with congenital heart disease, cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy
• Patients with cardiac surgery
• Patients with thyroid disease
• Patients with anemia
• Patients with pulmonary diseases
• Patients with infectious diseases (locally or systemic)

Trial design

710 participants in 2 patient groups

Cardiac Syndrome X

Control Group